Condition
Influenza Prophylaxis
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (1)
P 4 (2)
Trial Status
Completed3
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06762587Not ApplicableNot Yet Recruiting
Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting
NCT05255822Phase 2CompletedPrimary
INNA-051 Influenza Challenge Study
NCT01863849Phase 4CompletedPrimary
Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection
NCT01644149Phase 4CompletedPrimary
Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe
Showing all 4 trials